PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
32.68%
Net income growth of 32.68% while Healthcare median is zero at 0.00%. Walter Schloss would note a slight edge that could grow if sustained.
80.19%
D&A growth of 80.19% while Healthcare median is zero at 0.00%. Walter Schloss would question intangible or new expansions driving that cost difference.
-398.37%
Deferred tax shrinks yoy while Healthcare median is 0.00%. Seth Klarman would see potential advantage if actual tax outflows do not spike.
30.65%
SBC growth of 30.65% while Healthcare median is zero at 0.00%. Walter Schloss would question expansions or staff additions causing more equity grants.
27.89%
A slight increase while Healthcare median is negative at -6.97%. Peter Lynch might see peers reaping more free cash if they can do so without impacting sales.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-35.29%
AP shrinks yoy while Healthcare median is 0.00%. Seth Klarman would see better immediate cost coverage if top-line remains intact.
66.06%
Growth of 66.06% while Healthcare median is zero at 0.00%. Walter Schloss would question expansions or unusual one-time factors behind the difference.
30.65%
Growth of 30.65% while Healthcare median is zero at 0.00%. Walter Schloss would question expansions or one-off revaluations explaining the difference.
-19.98%
Negative CFO growth while Healthcare median is -9.25%. Seth Klarman would suspect a firm-specific operational weakness if peers maintain growth.
-32.37%
CapEx declines yoy while Healthcare median is 0.00%. Seth Klarman would note a short-term FCF advantage if revenue is stable.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-271.58%
Reduced investing yoy while Healthcare median is 0.00%. Seth Klarman sees potential advantage in near-term liquidity if revenue remains stable.
69.11%
Debt repayment growth of 69.11% while Healthcare median is zero at 0.00%. Walter Schloss wonders if expansions or a shift in capital structure drive that difference.
-69.14%
We reduce issuance yoy while Healthcare median is 0.00%. Seth Klarman might see an advantage in preserving per-share value unless expansions are neglected.
No Data
No Data available this quarter, please select a different quarter.